Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada

References

• Charles River AssociatesThe burden of acute coronary syndrome: The second leading cause of death in CanadaCharles River Associates’ Life Sciences Practice Available from: http://www.crai.ca/uploaded-Files/RELATING_MATERIALS/Publications/files/Burden%20of%20ACS%20in%20Canada_STC_151210Final%20(2).pdfAccessed November 4, 2011
   Google Scholar
• BellADRoussinACartierRThe use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelinesCan J Cardiol201127Suppl AS1S5921640290
   PubMed Web of Science ®Google Scholar
• YusufSZhaoFMehtaSRChrolaviciusSTognoniGFoxKKEffects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevationN Engl J Med2001345749450211519503
   PubMed Web of Science ®Google Scholar
• KuliczkowskiWWitkowskiAPolonskiLInterindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of CardiologyEur Heart J200930442643519174428
   PubMed Web of Science ®Google Scholar
• NguyenTADiodatiJGPharandCResistance to clopidogrel: a review of the evidenceJ Am Coll Cardiol20054581157116415837243
   PubMed Web of Science ®Google Scholar
• TanguayJ-FBellADAckmanMLFocused 2012 Update on the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapyCan J Cardiol8232013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• HustedSEmanuelssonHHeptinstallSSandsetPMWickensMPetersGPharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirinEur Heart J20062791038104716476694
   PubMed Web of Science ®Google Scholar
• WallentinLBeckerRCBudajATicagrelor versus clopidogrel in patients with acute coronary syndromesN Engl J Med2009361111045105719717846
   PubMed Web of Science ®Google Scholar
• TheidelUAsseburgCGiannitsisEKatusHCost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in GermanyClin Res Cardiol2013102644745823474908
   PubMed Web of Science ®Google Scholar
• ChinCTMellstromCChuaTSMatcharDBLifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspectiveSingapore Med J201354316917523546032
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceTicagrelor for the treatment of acute coronary syndromes (TA236)2011 Available from: http://publications.nice.org.uk/ticagrelor-for-the-treatment-of-acute-coronary-syndromes-ta236Accessed October 10, 2013
   Google Scholar
• NikolicEJanzonMHauchOWallentinLHenrikssonMCost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO studyEur Heart J201334322022822719022
   PubMed Web of Science ®Google Scholar
• LiewDDe Abreu LourencoRAdenaMChimLAylwardPCost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromesClin Ther20133581110111723891361
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in HealthCDEC Final Recommendation: Ticagrelor2011 Available from: http://www.cadth.ca/media/cdr/complete/cdr_complete_Brilinta_Dec-20-11.pdfAccessed October 11, 2013
   Google Scholar
• Ontario Ministry of Health and Long-Term CareUpdate at Ontario Drug Benefit Formulary/Comparative Drug Index No 41 Effective4302013 Available from: http://www.health.gov.on.ca/en/pro/programs/drugs/formulary/41_update_at_20130419.pdfAccessed October 11, 2013
   Google Scholar
• Canadian Agency for Drugs and Technologies in HealthGuidelines for the economic evaluation of health technologiesCanada3rd ed2006 Available from: http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdfAccessed October 11, 2013
   Google Scholar
• BriggsAClaxtonKSculpherMDecision Modelling For Health Economic EvaluationOxford, UKOxford University Press2006
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health Adapted from: Banerjee S, Brown A, McGahan L, et alClopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analysesTechnology Report, No 133Ottawa, CanadaCanadian Agency for Drugs and Technologies in Health2010 Available from: http://www.cadth.ca/media/pdf/cadth-2-1-02.pdfAccessed October 11, 2013
   Google Scholar
• KarnonJBrennanAPandorAModelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UKCurr Med Res Opin200521110111215881481
   PubMed Web of Science ®Google Scholar
• Statistics CanadaLife Tables, Canada, Provinces and Territories2011 Available from: http://www5.statcan.gc.ca/bsolc/olc-cel/olc-cel?catno=84-537-X&lang=engAccessed October 11, 2013
   Google Scholar
• LaceyEAWaltersSJContinuing inequality: gender and social class influences on self perceived health after a heart attackJ Epidemiol Community Health200357862262712883071
   PubMed Web of Science ®Google Scholar
• StoreyRFBeckerRCHarringtonRACharacterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomesEur Heart J201132232945295321804104
   PubMed Web of Science ®Google Scholar
• Ontario Case Costing Initiative2010 Available from: http://www.occp.com/Accessed October 11, 2013
   Google Scholar
• Ontario Ministry of Health and Long-Term CareOntario Health Insurance (OHIP) Schedule of Benefits and Fees (Physicians)2010 Available from: http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/physserv_mn.htmlAccessed October 11, 2013
   Google Scholar
• CrespinDJFederspielJJBiddleAKJonasDERossiJSTicagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysisValue Health201114448349121669373
   PubMed Web of Science ®Google Scholar
• LaupacisAFeenyDDetskyASTugwellPXHow attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluationsCMAJ199214644734811306034
   PubMed Web of Science ®Google Scholar